Pharmafile Logo

BioMarin Pharmaceutical Inc

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for BioMarin Pharmaceutical Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring BioMarin Pharmaceutical Inc.

Recent articles on PMLiVE featuring BioMarin Pharmaceutical Inc

Biomarin
BioMarin shares long-term results for haemophilia A gene therapy Roctavian

Approximately one in 10,000 people are affected by the genetic blood clotting disorder

- PMLiVE
The rise of biologics: is the sector ready for future demand?

Looking at the evolving biological sector and the various capacity challenges that global biopharma companies will have to bridge

- PMLiVE
EC approves BioMarin’s gene therapy Roctavian for severe haemophilia A

Approximately 20,000 adults are affected by haemophilia A across more than 70 countries in Europe, the Middle East and Africa

Biomarin
FDA pauses BioMarin gene therapy trial

The study for BMN 307 in genetic disease phenylketonuria will be paused while malignancies in mice are explored

- PMLiVE
Sourcing R&D innovation: why pharma companies need to evolve their business models

Recent years have seen a significant shift in drug development to specialty areas

- PMLiVE
Cortellis Drugs to Watch in 2020 report

The latest Cortellis Drugs to Watch report highlights medicines that treat high prevalence conditions

- PMLiVE
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price

Vowed to break patent if company goes ahead with proposed price

- PMLiVE
Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year’s tally

- PMLiVE
Bluebird Bio: on the cusp of a gene therapy revolution

Nick Leschly talks to PME about Bluebird’s remarkable gene therapy pipeline and why it’s filing first in Europe.

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links